Inventor · disambiguated record
Melanie K. Tallent
Also filed as: TALLENT MELANIE · TALLENT MELANIE K
6 granted patents·3 pending applications·41 citations·filing 2010–2021
80Inventor score
Top patents by PatentIndex Score
9 records- 0191US9359603B2Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of diseaseUNIV DREXEL·Filed 2014·Granted Jun 7, 2016·21 cites·20 claims
- 0287US8680254B2Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of diseaseLUTZ GORDON J·Filed 2010·Granted Mar 25, 2014·18 cites·20 claims
- 0378US9885049B2Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of diseaseUNIV DREXEL·Filed 2016·Granted Feb 6, 2018·2 cites·8 claims
- 0463US10337015B2Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of diseaseUNIV DREXEL·Filed 2018·Granted Jul 2, 2019·0 cites·8 claims
- 0561US10041075B2Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of diseaseUNIV DREXEL·Filed 2017·Granted Aug 7, 2018·0 cites·19 claims
- 0657US2022098596A1Splice modulating oligonucleotides and methods of use thereofLIFESPLICE PHARMA LLC·Filed 2021·Application pending·0 cites
- 0750US11198874B2SCN8A splice modulating oligonucleotides and methods of use thereofLIFESPLICE PHARMA LLC·Filed 2015·Granted Dec 14, 2021·0 cites·17 claims
- 0842US2022265864A1Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of useLIFESPLICE PHARMA LLC·Filed 2019·Application pending·0 cites
- 0941US2021246454A1Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of useLIFESPLICE PHARMA LLC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Melanie K. Tallent files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →